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Background: Recent studies have suggested that the metastasis-associated colon cancer1 (MACC1) gene can
promote tumor proliferation, invasion and metastasis through an upregulation of c-Met expression. However, its role
in gastric cancer is controversial. Our study investigated expression of MACC1 and c-Met in gastric cancer, as well as
correlated this with clinicopathological parameters.
Methods: Expressions of MACC1 and c-Met protein in a sample of 98 gastric carcinoma and adjacent nontumorous
tissues were detected by immunohistochemistry. Their relationships and correlations with clinicopathological
features were analyzed.
Results: The positive rates of MACC1 and c-Met protein in primary tumors were 61.22% and 59.18%, respectively. A
significant correlation was found between expression of MACC1 and c-Met (P<0.05). Expression of the MACC1
protein in gastric cancer tissue was correlated with lymph node metastasis (χ2 = 10.555,P = 0.001), peritoneal
metastasis (χ2 = 5.694, P = 0.017), and hepatic metastasis (χ2 = 4.540,P = 0.033), but not with age, gender, tumor size,
location, clinical stage or the distant metastases (P>0.05).
Conclusion: The positive rate of MACC1 protein expression was related to the protein expression of c-Met. Both
had a correlation with the presence of peritoneal metastasis, lymph node metastasis and hepatic metastasis, all of
which contribute to a poor prognosis for gastric cancer patients.
Keywords: Gastric cancer, Metastasis associated with colon cancer1, c-Met, Peritoneal metastasis, Lymph node
metastasis, Hepatic metastasisIntroduction
Gastric cancer is a common gastrointestinal malignancy.
Although the incidence of gastric cancer has declined dur-
ing the past years, it is still the fourth leading cause of
cancer-related death. Gastric cancer is the second most
frequent cause of cancer-associated death in malignant tu-
mors that accounts for about 10.4% [1]. An analysis of the
global incidence of cancer mortality showed that there are
nearly 900,000 new cases and 700,000 cancer deaths in the
world. The incidence of gastric cancer is significantly dif-
ferent in different countries and regions. Gastric cancer is
the second most frequently diagnosed cause of cancer
death in China [2]. Gastric cancer is a multifactorial dis-
ease with a complex interplay between genetics and both* Correspondence: hxdamingxu@hotmail.com
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reproduction in any medium, provided the orlifestyle and environmental factors, which consequently
results in malignant transformation and progression of
gastric cancer. Unfortunately, there has been no specific
signature of gastric cancer gene expression reported to
allow for patient-tailored therapy strategies. Accordingly,
there is great demand to further identify novel oncogenes
and clinically applicable molecular targets for the diagno-
sis and treatment of this disease.
Recent observations have suggested that the metastasis-
associated colon cancer1 (MACC1) gene can promote
tumor proliferation, invasion and metastasis, which is
an independent prognostic indicator of recurrence and
disease-free survival. The hepatocyte growth factor (HGF)/
mesenchymal–epithelial transition factor (c-Met) pathway
plays a key role in the carcinogenic pathway [3]. Hepatocyte
growth factor (HGF) is a glycoprotein secreted by a variety
of mesenchymal or tumor cells [4], which promote migra-
tion, invasion, wound healing and survival and suppress. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Correlation of clinicopathological parameters






(+) (-) P (+) (-) P
Age(years)
<55 41 24 17 0.643 25 16 0.760
≥55 57 36 21 33 24
Gender
Male 69 42 27 0.911 41 28 0.941
Female 29 18 11 17 12
Maximal tumor size(cm)
<5 54 34 20 0.696 35 19 0.209
≥5 44 26 18 23 21
Tumor location
Cardia, fundic, body 43 30 13 0.125 29 14 0.141
Antral 55 30 25 29 26
Histology
Well differentiated 39 20 19 0.101 20 19 0.196
Poorly differentiated 59 40 19 38 21
Lymphnode metastasis
Yes 72 51 21 0.001* 47 25 0.041*
No 26 9 17 11 15
Peritoneal dissemination
Yes 26 21 5 0.017* 20 6 0.032*
No 72 39 33 38 34
Hepatic metastasis
Yes 18 15 3 0.033* 15 3 0.021*
No 80 45 35 43 37
TNM stage
I,II 43 23 20 0.165 22 21 0.153
III,IV 55 37 18 36 19
MACC1
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the mitogen-activated protein kinase (MAPK) and PI3K–
AKT pathways. MACC1 was reported to be elevated in
various cancer tissues, including ovarian cancer [5], hepato-
cellular carcinoma [6], non-small cell lung cancer [7], and
oral squamous cell carcinoma [8]. Recently, there have been
reports demonstrating that MACC1 may be involved in the
growth of blood vessels, lymphangiogenesis and metastasis
of gastric cancer [9-11], but little is known regarding its role
in gastric cancer development.
MACC1 may be involved in the development of gastric
cancer through the HGF/c-Met pathway, or as an inde-
pendent factor in the gastric process, or through other
pathways. MACC1 may become a new molecular marker
and target for the diagnosis and treatment of gastric can-
cer proliferation and metastasis. In the present study, we
investigated MACC1 and c-Met expression by immuno-
histochemistry and real-time polymerase chain reaction
(RT-PCR) and analyzed the relationship, as well as correl-
ating it with clinicopathological parameters and their clin-
ical significance.
Materials and methods
Patients and tumor specimens
Ninety-eight cases of gastric cancer tissues and adjacent
noncancerous mucosa were collected at Gansu Provin-
cial Hospital from Apr 2006 to Feb 2007. Tissue samples
for diagnostic purposes were obtained with the consent
of each patient. All tumor specimens and corresponding
normal tissues were fixed in 10% buffered formalin, em-
bedded in paraffin, and then made into continuous 4 μm
tissue sections for immunohistochemical examination.
All patients had been histologically diagnosed without pre-
operative radiotherapy, chemotherapy or other anti-cancer
therapy. All of the cases received postoperative adjuvant
chemotherapy, and all specimens were pathologically con-
firmed. The study group consisted of 98 patients, 69 males
and 29 females, aged 17 to 79 years, the average age
(65.34 ± 13.40) years, and the median age 58 years. The
staging of gastric cancer was according to the American
Joint Committee on Cancer (ACJJ, 7th edition) (Table 1).
Rabbit anti-human MACC1 and c-Met antibodies were
purchased from Beijing Biosynthesis Biotechnology Co.,
Ltd., SP immunohistochemical detection kit. DAB chromo-
genic kit was purchased from Beijing Zhongshan Golden
Bridge Biotechnology Co., Ltd.
Immunohistochemistry (IHC)
Gastric cancer tissues paraffin sections were placed in
citrate buffer (pH 6.0) for antigen retrieval. The negative
control antibody was replaced by PBS. The positive
controls were lung adenocarcinoma specimens express-
ing MACC1, and c-Met expression of hepatocellular car-
cinoma. The procedure was in accordance with theimmunohistochemical SP detection kit instructions. The
diluted density of rabbit anti-human MACC1 antibody
was 1:100 and c-Met antibody was 1:150. MACC1 and c-
Met protein positive products were mainly localized in the
cytoplasm. A small number of nuclear membranes were
colored pale-brown with a diffuse distribution.
Evaluation of IHC staining
Positive results were judged by semi-quantitative points
[9]. The staining intensity score was 0 (negative), 1 (weak),
2 (medium), and 3 (strong). The integral of the rate of
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and 4 (76-100%). The proportional score and the intensity
score were then added to obtain a total score. A score ≥ 3
was considered to be a positive expression.
Statistics
SPSS 16.0 statistical software was used for analysis, and
count data used the χ2 test. The Kaplan-Meier method
was used to estimate cumulative survival as a function
of time, and survival differences were analyzed with the
log-rank test. The inspection level α = 0.05.
Results
MACC1 and c-Met protein expression in gastric cancer
tissues and adjacent normal tissue
Immunohistochemical results showed that the positive rate
of MACC1 in the 98 tumor tissues was 61.22% (60/98). It
was significantly higher than in the corresponding normal
tissues (9.18%, 9/98) and the difference was statistically sig-
nificant (χ2 = 58.176, P<0.05) (Figure 1). The positive rate of
c-Met in the 98 tumor tissues was 59.18% (58/98). It was
significantly higher than in the corresponding normal tis-
sues (10.20%, 10/98) and the difference was statistically sig-
nificant (χ2 = 51.882, P<0.05) (Figure 2).
Correlation of clinicopathological parameters with MACC1
and c-Met Expression
Immunohistochemical expression of MACC1 in gastric
cancer tissues and the statistical analysis of clinical
pathological data of patients showed that there was a
close relationship between MACC1 which was highlyFigure 1 Representative IHC staining (SP × 100). A: Positive labeling for
carcinoma. B: Negative staining for MACC1 is shown in primary gastric carc
D: Negative expression in adjacent noncancerous mucosa.expressed in tumors and lymph metastasis, peritoneal
metastasis and hepatic metastasis. P values were 0.001,
0.017, 0.033, 0.001 respectively and the difference was
statistically significant (Table 1). There was no associ-
ation with age, gender, tumor size, location, clinical stage
or the degree of histological differentiation (P>0.05). Ex-
pression of c-Met protein in the gastric cancer tissue
was correlated with lymph node metastasis (χ2 = 4.172,
P = 0.041), peritoneal metastasis (χ2 = 4.610, P = 0.032),
and hepatic metastasis (χ2 = 5.323, P = 0.021), but not
with age, gender, tumor size, location, clinical stage or
the degree of histological differentiation (P>0.05).
MACC1 and c-Met expression correlated with patient
survival in gastric cancer
MACC1 protein was closely related to expression of c-Met
in gastric cancer tissues, P = 0.002 (Table 1). As shown in
Figure 3, the survival rate of MACC1 negative patients was
significantly higher than in the positive expression group
(χ2 = 4.386, P = 0.036). However, the survival rates were sig-
nificantly different between the c-Met protein positive and
negative groups of patients (χ2 = 5.072, P = 0.024).
Discussion
Recently, Stein et al. [3] identified the metastasis associ-
ated with the colon cancer 1 (MACC1) gene by genome-
wide expression analysis in primary tumors, metastases
and normal mucosa of subjects with colon cancer. They
also observed that MACC1 mRNA expression in colo-
rectal carcinoma might be an independent prognostic in-
dicator of metastasis formation and disease-free survival.MACC1 with brown stained cytoplasm is shown in primary gastric
inoma. C: MACC1 protein expression in adjacent normal tissues
Figure 2 C-Met protein expression determined by IHC staining in gastric carcinoma and adjacent normal tissues (SP × 100).
A: c-Met protein expression in gastric cancer. B: Negative expression in gastric cancer. C: Positive staining for c-Met in adjacent normal mucosa.
D: Negative staining for c-Met protein.
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(7p21.1), contains seven exons and six introns, and the
effective coding region of the gene is constituted of 2559
nucleotides. MACC1 encodes a putative protein of 852
amino acids. The main structure can be divided into
four regions: the ZU5, SH3, and the two C-terminal hy-
droxyl death domains (DD).
Subsequent study found that there is a close relation-
ship between MACC1 and proliferation, metastasis and
recurrence of a variety of tumors. Previous studies haveFigure 3 Kaplan-Meier survival curves of patients with gastric cancer
Correlation between overall survival of the patients and MACC1 expression
that between survival and c-Met expression (log rank p = 0.0024).demonstrated that overexpression of MACC1 in lung
adenocarcinoma is an independent risk factor for recur-
rence, and is closely related to the survival rate for patients
[12-14]. MACC1 expression is significantly related to vas-
cular invasion and alpha-fetoprotein level, which might
serve as a novel prognostic marker in hepatocellular car-
cinoma [15]. The positive rate of MACC1 protein expres-
sion is related to the protein expression c-Met as shown
by QRT-PCR in primary hepatocellular carcinoma and is
closely related to recurrence and disease-free survival.according to MACC1 (A) and c-Met (B) protein expression.
was found to be statistically significant (log rank p = 0.036) as well as
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the TNM Ι stage have a poorer prognosis compared with
those with expression-negative tumors [16]. MACC1 ex-
pression in ovarian cancer was significantly higher in pri-
mary tumors than in normal tissues. We found that high
levels of MACC1 often correlated with enhanced lymph
node metastasis, distant metastasis and the clinicopatho-
logical stage [17]. MACC1 specific small hairpin RNA
(shRNA) expression plasmids were constructed and trans-
fected into OVCAR-3 cells, which decreased expression of
MACC1 and resulted in significant inhibition of cell pro-
liferation, migration and invasion, with obvious enhance-
ment of apoptosis [18].
Expression of the MACC1 protein through up-
regulation of c-Met is by action on the Sp1 sites, which is
the c-Met startup sequence that enhances the cascade ef-
fect of HGF/c-Met signaling pathways [19]. Our results
suggest that MACC1 protein expression is consistent with
c-Met expression in gastric cancer specimens, which was
up-regulated along with the progression of gastric cancer.
These results suggest that MACC1 may act as a new par-
ameter for predicting poor prognosis of gastric cancer.
Thus, the current findings provide evidence that positive
expressions of MACC1 and c-Met in gastric cancer are
significantly higher in primary tumors which developed
lymph node metastasis, compared to those with no metas-
tasis. It indicates that the MACC1 protein can promote
lymph node metastasis through the HGF/c-Met pathway.
Research has shown that the HGF/c-Met pathway is re-
lated to gastric cancer lymphangiogenesis [20], which dir-
ectly or indirectly promotes lymph node metastasis
through the VEGF-C/VEGF-D/VEGFR-3 axis [21,22].
Taken together, these results revealed that the MACC1
protein can forecast lymph node metastasis, but the spe-
cific mechanism of how it is involved in lymph node me-
tastasis needs further examination.
Peritoneal metastasis is a common sign of advanced
tumor stage, tumor progression, or disease recurrence in
patients with gastric cancer [23]. Our study shows that
positive protein expression of c-Met and MACC1 seems
to be related to the peritoneal metastasis of gastric can-
cer, which is consistent with Shirahata, A [24] related
conclusions. MACC1 expression might be an indicator
for peritoneal dissemination of gastric cancer, but its
specific mechanism is unclear. Toiyama, Y. et. al [25]
demonstrated that the HGF/c-Met pathway induces epi-
thelial mesencymal transition (EMT), which has the po-
tential to promote peritoneal dissemination in gastric
cancer. Epithelial–mesenchymal transition (EMT) allows
epithelial cells to have mesenchymal-cell characteristics
and to acquire the more invasive characteristics of mes-
enchymal cells, which is also involved in metastasis [26].
The EMT process of tumor development can facilitate
migration and invasion of epithelial tumor cells [27].Another clinical result showed a strong correlation be-
tween expression of HGF/c-Met and abnormal expression
of E-cadherin in tumor cells, which can be viewed as both a
cause and effect of EMT [20]. We speculate that the
MACC1 protein may induce the process of EMT in gastric
cancer cells through the HGF/c-Met pathway, and conse-
quently influences the peritoneal metastasis of gastric can-
cer. Therefore, determination of this mechanism might
provide clinically useful information for peritoneal dissem-
ination and prognosis in patients with gastric cancer.
The five-year survival rate for gastric cancer patients
with liver metastases remains less than 5% [28], and
there are still no effective means of prevention and treat-
ment [29]. The present study confirmed that c-Met was
closely related to liver metastasis of gastric cancer which
is consistent with the literature [9]. Also, high MACC1
protein expression was significantly associated with liver
metastasis of gastric cancer. It suggested that MACC1
might play an important role in the progress of liver me-
tastases from gastric carcinoma. MACC1 may be used as
a new predictive molecular marker of liver metastasis of
gastric cancer, and down-regulation of MACC1 may
provide a novel method for blocking the process of liver
metastasis from gastric cancer. More experiments are
needed to verify these hypotheses.
Our results which are consistent with the majority of
cancer research suggest that MACC1 and c-Met are the
poor prognostic indicators of gastric cancer, which are dif-
ferent from Ge Sh et al. [30] findings. When Stein elabo-
rated the mechanism of MACC1 protein, she reported
that MACC1 mutants lacking the SH3 domain or prolin-
rich sequence abrogated the binding of MACC1 to the
Met promoter [31]. More research on this is needed in the
future.
In conclusion, it was found that expression of MACC1
correlated with c-Met expression and that both of them
correlated with the presence of lymph node metastasis,
peritoneal metastasis, and hepatic metastasis in gastric
carcinoma. These results suggest that MACC1 and c-Met
may serve as parameters for the prognostic prediction of
gastric cancer. Furthermore, the specific mechanisms that
are involved in the progression of gastric cancer needs fur-
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